BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15806125)

  • 41. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Benson DM; Elder PJ; Lin TS; Blum W; Penza S; Avalos B; Copelan E; Farag SS
    Leuk Res; 2007 Aug; 31(8):1069-75. PubMed ID: 17070906
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
    Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
    Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
    Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
    Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
    Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
    J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
    Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Tc-99 measurement of glomerular filtration rate vs. calculated creatinine clearance to assess renal function pretransplant in pediatric patients undergoing hematopoietic stem cell transplantation.
    Kletzel M; Pirich L; Haut P; Cohn RA
    Pediatr Transplant; 2005 Oct; 9(5):584-8. PubMed ID: 16176414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation.
    Schnabel B; Schmidmaier R; Franke D; Emmerich B; Straka C
    Cytotherapy; 2006; 8(5):473-9. PubMed ID: 17050252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
    Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
    Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia.
    Liu H; Ding JH; Liu BC; Zhao G; Chen BA
    Am J Nephrol; 2007; 27(4):336-41. PubMed ID: 17519537
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
    Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
    Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
    Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
    J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
    Imataki O; Aoyama T; Tamai Y; Kawakami K
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation.
    Mølle I; Peterslund NA; Thiel S; Steffensen R
    Bone Marrow Transplant; 2006 Oct; 38(8):555-60. PubMed ID: 16953214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma.
    Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Leung N; Gastineau DA
    Bone Marrow Transplant; 2007 May; 39(10):605-11. PubMed ID: 17369867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Iohexol clearance for GFR-determination in renal failure--single or multiple plasma sampling?
    Sterner G; Frennby B; Hultberg B; Almen T
    Nephrol Dial Transplant; 1996 Mar; 11(3):521-5. PubMed ID: 8671824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.